SCHEMBL29846348

SCHEMBL29846348

CC(C)(C)OC(=O)NC(c1ccc(F)cc1)S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.43
CTSK P43235 4/20 0.43
ABCB1 P08183 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MMP13 P45452 2/20 0.41
ATM Q13315 4/20 0.41
MAPT P10636 2/20 0.40
GABRB1 P18505 1/20 0.40
GABRB2 P47870 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
BCL2 P10415 1/20 0.39
JAK2 O60674 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8777246 0.91 CTSK (0.49) CTSSCTSKABCB1MMP13ATM
SCHEMBL23205656 0.88 S1PR3 (0.45) CTSSCTSKABCB1MMP13ATM
SCHEMBL12838215 0.86 NPC1 (0.49) CTSSCTSKABCB1MMP13MAPT
SCHEMBL31477403 0.82 CTSS (0.44) CTSSCTSKABCB1MMP13ATM
SCHEMBL6915011 0.81 CYP3A4 (0.45) CTSSCTSKMEN1KMT2AMMP13
SCHEMBL28588129 0.80 CTSL (0.45) CTSSCTSKABCB1MMP13ATM
SCHEMBL12293491 0.80 NAMPT (0.48) CTSSCTSKABCB1ATMMAPT
SCHEMBL10216722 0.78 LMNA (0.44) CTSSCTSKABCB1MEN1KMT2A
SCHEMBL10217082 0.78 ATM (0.43) CTSSCTSKABCB1MMP13ATM
SCHEMBL1542093 0.77 ABCB1 (0.51) CTSSCTSKABCB1MMP13ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486231-B2 Targeted nitroxide compounds and their use in treating ferroptosis-related diseases University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-12-02 US disclosed
US-20220259149-A1 Targeted Nitroxide Compounds and Their Use in Treating Ferroptosis-Related Diseases DEFENSE THREAT REDUCTION AGENCY, US DOD 2022-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486231-B2 Targeted nitroxide compounds and their use in treating ferroptosis-related diseases HMOX1, AIFM2, HMOX2 CTSS 1785/4885CTSK 1410/4885ABCB1 2481/4885
US-20220259149-A1 Targeted Nitroxide Compounds and Their Use in Treating Ferroptosis-Related Diseases HMOX1, AIFM2, HMOX2 CTSS 1785/4885CTSK 1410/4885ABCB1 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.